NEW INDAZOLE DERIVATIVES

Claims

1. Compound of formula (I): Where R 1 and R 2 independently selected from alkyl, or R 1 and R 2 together with the carbon to which they are attached, they form a cycloalkyl; R 3 is alkyl or haloalkyl; and R 4 is hydrogen or halogen; or a pharmaceutically acceptable salt thereof.

2. The compound according to item 1, where R 1 and R 2 are methyl, or R 1 and R 2 together with the carbon to which they are attached, they form cyclopropyl.

3. The compound according to item 1 or 2, where R 1 and R 2 together with the carbon to which they are attached, they form cyclopropyl.

4. The compound according to item 1 or 2, where R 1 and R 2 are methyl.

5. A connection according to any of paragraphs 1-4, where R 3 is methyl.

6. A connection according to any of paragraphs 1-5, where R 4 represents hydrogen or fluorine.

7. A connection according to any of paragraphs 1-6, where R 4 is hydrogen.

8. A connection according to any of paragraphs 1-6, where R 4 represents fluorine.

9. A compound selected from: 2-[4-(difluoromethyl)-7-methyl-6-(4-morpholinophenyl)indazol-2-yl]-2-spiro[6,7-dihydropyrrolo[1,2-c]imidazol-5,1'-cyclopropan]-1-yl-N-thiazol-2-ylacetamide; 2-[7-methyl-6-(4-morpholinophenyl)-4-(trifluoromethyl)indazol-2-yl]-2-spiro[6,7-dihydropyrrolo[1,2-c]imidazol-5,1'-cyclopropan]-1-yl-N-thiazol-2-ylacetamide; and 2-(5,5-dimethyl-6,7-dihydropyrrolo[1,2-c]imidazol-1-yl)-2-[7-methyl-6-(4-morpholinophenyl)-4-(trifluoromethyl)indazol-2-yl]-N-thiazol-2-ylacetamide; or a pharmaceutically acceptable salt thereof.

10. A method for producing a compound according to any one of claims 1-9, comprising at least one of the following steps: (a) the reaction of the compound of formula (B1): in a suitable solvent and in the presence of a base, to obtain a compound of formula (B2): where M + is Na + , Li + or protonated base; (b) reacting a compound of formula (B2) in a suitable solvent and in the presence of an acid to obtain a compound of formula (B3): (c) the reaction of the compound of formula (B3) with the compound of formula (B4): in the presence of a suitable binding agent and base; where R 1 , R 2 , R 3 and R 4 are as defined in any one of paragraphs 1-9; and wherein R is H or alkyl.

11. A connection according to any one of paragraphs 1-9, manufactured in accordance with the method according to paragraph 10.

12. A compound according to any one of claims 1 to 9 for use as a therapeutically active substance.

13. A pharmaceutical composition comprising a compound according to any one of claims 1-9 and a therapeutically inert carrier.

14. A compound according to any one of claims 1 to 9 for use in the treatment or prevention of cancer, in particular non-small cell lung cancer.

15. The use of a compound according to any one of claims 1 to 9 for use in the treatment or prevention of cancer, in particular non-small cell lung cancer.

16. Use of a compound according to any one of claims 1 to 9 for the production of a medicinal product for the treatment or prevention of cancer, in particular non-small cell lung cancer.

17. A method for treating or preventing cancer, in particular non-small cell lung cancer, said method comprising administering an effective amount of a compound as defined in any one of claims 1-9 to a patient in need thereof.